Target Audience
This activity is intended for medical oncologists, radiation oncologists, surgeons, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.
Learning Objectives
Upon completion of this activity, participants should be able to
- Appraise available findings from clinical research studies investigating anti-PD-1/PD-L1 antibody consolidation for limited-stage small cell lung cancer (SCLC) in patients who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and determine the role of this approach for appropriate individuals.
- Review long-term data supporting the use of anti-PD-1/PD-L1 antibodies in combination with platinum-based chemotherapy as first-line therapy for patients with extensive-stage SCLC, and consider how these regimens can be appropriately and safely integrated into clinical practice.
- Appreciate the biological rationale for the evaluation of maintenance treatment after chemoimmunotherapy induction for extensive-stage SCLC, and assess available research findings with and the current role of this therapeutic approach.
- Evaluate available clinical trial findings with FDA-approved agents for patients with SCLC who experience disease progression on or after platinum-containing first-line therapy, and determine how to optimally integrate these therapies into current treatment algorithms.
- Appreciate the incidence of B7-H3 overexpression in patients with SCLC, and develop an understanding of the rationale for, available data with and ongoing studies of B7-H3-directed antibody-drug conjugates in individuals with relapsed/refractory disease.
- Assess ongoing clinical research studies evaluating other novel agents and treatment strategies under development for the management of SCLC, and counsel patients regarding the potential benefits of trial participation.
CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.
American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn up to 1 Medical Knowledge MOC point toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY
— The following faculty reported relevant financial relationships with ineligible entities:
Dr Hann —
Advisory Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group;
Consulting Agreements: AbbVie Inc;
Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc.
Dr Sands —
Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Catalyst Pharmaceuticals Inc, Daiichi Sankyo Inc, Fosun Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Lilly, Merck, Novartis, Pfizer Inc, PharmaMar, Sanofi;
Contracted Research: Amgen Inc, Novartis.
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Merck, and Puma Biotechnology Inc.
